CRNX 52.77 (-0.42%)
US22663K1079BiotechnologyBiotechnology

Crinetics Pharmaceuticals (CRNX) Stock Highlights

52.77 | -0.42%
2024-09-19 01:14:00
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidates include paltusotine which is in clinical development for the treatment of acromegaly and neuroendocrine tumors, or NETs, CRN04777, which is in clinical development for congenital hyperinsulinism, or HI, and CRN04894, which is in clinical development for diseases of excess adrenocorticotrophic hormone, or ACTH, including Cushings Disease, congenital adrenal hyperplasia, or CAH, and Ectopic ACTH Syndrome, or EAS.

Statistics

Range Today
52.06 53.85
Volume Today 761.46K
Range 1 Year
25.35 55.78
Volume 1 Year 209.09M
Range 3 Year
15.23 55.78
Volume 3 Year 433.61M
Range 10 Year
10.63 55.78
Volume 10 Year 529.36M

Highlights

Market Capitalization 4.31B (mid)
Floating Shares 74.6M
Current Price 52.77
Price To Earnings -13.83
Price To Revenue 2.38K
Price To Book 5.14
Earnings Per Share -3.76
Payout Ratio 0%

Performance

Latest -0.42%
1 Month +2.31%
3 Months +18.19%
6 Months +37.39%
1 Year +80.72%
3 Years +134.85%
5 Years +199.15%
10 Years +174.13%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.